Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 38kWORD 9k
2 July 2020
E-003939/2020
Question for written answer E-003939/2020
to the Commission
Rule 138
Tudor Ciuhodaru (S&D)
 Answer in writing 
 Subject: European vaccine against COVID-19

The COVID-19 crisis has triggered keen competition among researchers and internationally-renowned institutions in Europe and the rest of the world in the quest to produce a vaccine against the disease. With continuing reports of many new infections and cases requiring costly hospital treatment, the race to find viable solutions is all the more important and urgent.

Will the Commission provide dedicated COVID-19 support, or even additional funding, for research institutes in Europe with a view to establishing a European network for vaccine research, development and production – with the involvement of the Cantacuzino Institute, which is already part of the Louis Pasteur network – that can play a major strategic role at EU level and minimise the prospect of a vaccine being produced outside the EU?

Original language of question: RO
Last updated: 17 July 2020Legal notice - Privacy policy